Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 18/20 | 0.67 |
| ▸ | PPARG | P37231 | 7/20 | 0.67 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.58 |
| ▸ | WNT3A | P56704 | 1/20 | 0.58 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3025736 | 0.84 | ROCK2 (0.57) | EPHX2PPARGCTNNB1WNT3AROCK2 | |
| SCHEMBL5407860 | 0.82 | CTNNB1 (0.60) | EPHX2PPARGCTNNB1WNT3AROCK2 | |
| SCHEMBL9764513 | 0.79 | CTNNB1 (0.58) | EPHX2CTNNB1WNT3AROCK1 | |
| SCHEMBL8535075 | 0.77 | HDAC1 (0.55) | EPHX2PPARGCTNNB1WNT3A | |
| SCHEMBL5643051 | 0.77 | EPHX2 (0.79) | EPHX2PPARG | |
| SCHEMBL3470247 | 0.75 | EPHX2 (0.58) | EPHX2PPARGROCK2ROCK1 | |
| SCHEMBL28207104 | 0.75 | EPHX2 (0.71) | EPHX2PPARG | |
| SCHEMBL3430846 | 0.75 | CHRNA7 (0.58) | EPHX2PPARG | |
| SCHEMBL1222115 | 0.75 | CTNNB1 (0.56) | EPHX2PPARGCTNNB1WNT3A | |
| SCHEMBL3470919 | 0.74 | EPHX2 (0.54) | EPHX2PPARGROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261743-A1 | NOVEL SEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261743-A1 | NOVEL SEH INHIBITORS AND THEIR USE | EPHX1, REN, NCEH1 | EPHX2 9/4885PPARG 3681/4885CTNNB1 3103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.